Aradigm Corporation (ARDM)
-OTC BB 0.15 
0.01(4.70%) May 24, 3:57PM EDT
| Prev Close: | 0.16 |
|---|
| Open: | 0.15 |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 1.00 |
|---|
| Beta: | 0.79 |
|---|
| Next Earnings Date: | 5-Aug-13 |
|---|
| Day's Range: | 0.14 - 0.16 |
|---|
| 52wk Range: | 0.09 - 0.18 |
|---|
| Volume: | 114,464 |
|---|
| Avg Vol (3m): | 103,331 |
|---|
| Market Cap: | 37.49M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.05 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- ARADIGM CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities,EDGAR Online(Fri, May 24)
- ARADIGM CORP FinancialsEDGAR Online Financials(Tue, May 21)
- Grifols, S.A. and Aradigm Corporation Announce Signing of Worldwide Licensing Agreement to Develop and Commercialize Pulmaquin™Business Wire(Tue, May 21)
- Grifols signs deal to license Aradigm's Pulmaquinat Reuters(Tue, May 21)
- ARADIGM CORP Files SEC form 10-Q, Quarterly ReportEDGAR Online(Tue, May 14)
- Aradigm Announces First Quarter 2013 Financial ResultsBusiness Wire(Tue, May 14)
- ARADIGM CORP Files SEC form 8-K, Change in Directors or Principal OfficersEDGAR Online(Thu, Mar 28)
- ARADIGM CORP Files SEC form 10-K, Annual ReportEDGAR Online(Wed, Mar 27)
- Aradigm Announces Fourth Quarter 2012 and Full Year Financial ResultsBusiness Wire(Tue, Mar 26)
- ARADIGM CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsEDGAR Online(Tue, Mar 26)
- Aradigm to Present at the Biotechnology Industry Organization (BIO) CEO & Investor Conference 2013 on February 12Business Wire(Wed, Feb 6)
- Aradigm to Present at Biotech Showcase 2013 on January 9Business Wire(Thu, Jan 3)
- ARADIGM CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities,EDGAR Online(Thu, Dec 13)
- Aradigm Announces Private Placement for $6 MillionBusiness Wire(Wed, Dec 12)
- UK Scientists Report on Efficacy of Aradigm’s Lipoquin™ Against Pneumonic PlagueBusiness Wire(Mon, Nov 19)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 39.18 |
|---|
| Ex-Dividend Date: | 01-Mar-96 |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.04 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.01 |
|---|
| Mean Recommendation*: | 1.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Aradigm Corporation, a specialty pharmaceutical company, focuses on the development and commercialization of drugs delivered by inhalation for the prevention and treatment of severe respiratory diseases by pulmonologists.
View More